Mechanisms of Action

The unique combination of properties based on secretion of diverse biomolecules underscores the importance of mesenchymal adult lineage stem cells (MLCs) as a platform for the development of cell-based regenerative medicine therapies. Our lead MLC products have been developed through proprietary processes optimized to express certain biomolecules implicated in the mechanisms of action by which the MLC product is thought to modify outcomes for the specific target condition.

Examples of our products and the biomolecules involved in their characterization are:

    • RYONCIL™ (remestemcel-L) is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in steroid-refractory acute graft versus host disease by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.
    • REVASCOR® is designed for local delivery to damaged heart muscle and to allow the MLCs to secrete biomolecules involved in myocardial neovascularization, cardiomyocyte survival, cardiomyocyte precursor migration and proliferation, and reduction in fibrosis and myocardial scarring. Biomolecules include stromal cell-derived factor 1, Angiopoietin-1, vascular endothelial growth factor (VEGF), hepatocyte growth factor, and matrix metalloproteinases.
    • MPC-06-ID is administered by local delivery to degenerating intervertebral discs to allow our MLCs to secrete biomolecules involved in enhanced migration and proliferation of intervertebral disc progenitor cells, and in enhanced proteoglycan and collagen synthesis in the disc nucleus and annulus. These biomolecules include Angiopoietin-1 and transforming growth factor beta.